Randomized Comparison of a High Clopidogrel Maintenance Dose in Patients With Diabetes Mellitus and Coronary Artery Disease

Results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) Study

Dominick J. Angiolillo, MD, PhD; Steven B. Shoemaker, MD; Bhaloo Desai, PhD; Hang Yuan, PhD; Ronald K. Charlton, PhD; Esther Bernardo, BSc; Martin M. Zenni, MD; Luis A. Guzman, MD; Theodore A. Bass, MD; Marco A. Costa, MD, PhD

Background—After treatment with clopidogrel, patients with type 2 diabetes mellitus (T2DM) have reduced platelet inhibition compared with patients who are not diabetic. Whether platelet inhibition can be enhanced by increasing clopidogrel maintenance dosage in T2DM patients is unknown. The aim of this pilot study was to assess the functional impact of a high maintenance dose in T2DM patients with suboptimal clopidogrel-induced antiplatelet effects.

Methods and Results—T2DM patients on chronic dual antiplatelet therapy were screened to identify suboptimal clopidogrel responders. The latter were randomized to 30-day treatment with a standard (75 mg; n=20) or high (150 mg; n=20) daily maintenance dose. Platelet function was assessed at 3 time points: baseline, 30 days after randomization, and 30 days after resuming standard dosing. Platelet function parameters included adenosine diphosphate–induced (20 and 5 \(\mu\)mol/L) maximal and late platelet aggregation, inhibition of platelet aggregation, platelet disaggregation, and P2Y\(_{12}\) reactivity index. A total of 64 T2DM patients were screened to identify 40 suboptimal responders. After randomization, maximal adenosine diphosphate–induced (20 \(\mu\)mol/L) platelet aggregation was significantly reduced in the 150-mg group compared with the 75-mg group (P=0.002; primary end point). However, suboptimal clopidogrel response was still present in 60% of patients on the 150-mg regimen. All other platelet function parameters showed enhanced clopidogrel-induced antiplatelet effects with 150 mg, which returned to baseline values after resumption of standard dosing.

Conclusions—A 150-mg maintenance dose of clopidogrel is associated with enhanced antiplatelet effects compared with 75 mg in high-risk T2DM patients. However, enhanced ex vivo platelet reactivity continues to persist, the clinical implications of which are unknown and need to be evaluated in large-scale clinical trials. (Circulation. 2007;115:708-716.)

Key Words: clopidogrel ■ diabetes mellitus ■ platelets ■ thrombosis

The P2Y\(_{12}\) receptor plays a pivotal role in platelet aggregation.\(^1\) This role is emphasized by the results of clinical trials that demonstrate improvement of long-term clinical outcomes in patients treated with the P2Y\(_{12}\) receptor antagonist clopidogrel.\(^2\)-\(^4\) However, a high interindividual variability in platelet response to clopidogrel has been described.\(^5\),\(^6\) The fact that subjects with suboptimal platelet inhibition by clopidogrel are at increased risk of cardiovascular ischemic events\(^7\)-\(^10\) represents an alarming clinical problem.

Clinical Perspective p 716

Inadequate dosing has been postulated as one of the mechanisms for suboptimal clopidogrel-induced antiplatelet effects.\(^11\),\(^12\) Previous investigations have shown that administration of a higher clopidogrel loading dose enhances platelet inhibition and leads to better response profiles than standard dosing.\(^11\),\(^12\) In addition, results from small studies suggest that, in patients undergoing percutaneous coronary interventions, the use of a high loading dose of clopidogrel may improve clinical outcomes.\(^13\),\(^14\) Despite the short-term improvement in platelet response with high loading dosage regimens of clopidogrel, patients may continue to have elevated platelet reactivity in the maintenance phase of antiplatelet therapy.\(^15\)-\(^19\) Of note, readministration of a loading dose of clopidogrel in patients already on maintenance therapy is associated with improved outcomes.\(^20\)

Received October 3, 2006; accepted December 19, 2006.


Correspondence to Dr Dominick J Angiolillo, Division of Cardiology University of Florida, Shands Jacksonville, 655 West 8th Street, Jacksonville, FL 32209. E-mail dominick.angiolillo@jax.ufl.edu

© 2007 American Heart Association, Inc.

Circulation is available at http://www.circulationaha.org DOI: 10.1161/CIRCULATIONAHA.106.667741

708
Patients with type 2 diabetes mellitus and coronary artery disease on standard aspirin plus clopidogrel therapy for > one-month

Study time point 1

Platelet function testing to define clopidogrel responsiveness

Suboptimal responders

Optimal responders

Randomization

Non eligible for randomization

150 mg clopidogrel/day for 30 days (n=20)

75 mg clopidogrel/day for 30 days (n=20)

Study time point 2

Platelet function testing

75 mg clopidogrel/day for 30 days

Study time point 3

Platelet function testing

Figure 1. Flow diagram of the study.

Methods

Patient Population and Study Design

Patients were eligible for the study if they had T2DM according to criteria from the World Health Organization Report, were on insulin or oral hypoglycemic medication, and were between the ages of 25 and 80 years. All patients included had documented CAD, as all patients had previously undergone percutaneous coronary interventions, and were in a steady state phase of clopidogrel treatment (75 mg daily). Pharmacokinetic and pharmacodynamic profiles may vary profoundly in the initial days or weeks after initiation of dual antiplatelet therapy. Thus, only patients in the maintenance phase of treatment (>30 days from initiation) were included. All patients were also treated with low-dose aspirin (81 mg daily). This dose of aspirin was chosen to reduce bleeding risk in patients on dual antiplatelet therapy. Major exclusion criteria included known allergies to aspirin or clopidogrel; impaired glucose tolerance or T2DM without pharmacological treatment; gestational diabetes, or transient hyperglycemia; blood dyscrasia; serum creatinine level >2 mg/dL; active bleeding or bleeding diathesis; gastrointestinal bleeding within prior 6 months; hemodynamic instability; cerebrovascular accident within 3 months; any malignancy; concomitant use of other antithrombotic drugs such as oral anticoagulants, dipyridamole, ticlopidine, or cilostazol, or nonsteroid anti-inflammatory drugs; recent treatment (<30 days before enrollment) with a glycoprotein Ib/IIa antagonist; platelet count <100×10^9/L; hematocrit <25%; liver disease (bilirubin level >2 mg/dL).

The Optimizing anti-Platelet Therapy In diabetes MellitusUS (OPTIMUS) study was a randomized, single-center, prospective, parallel-group platelet function study of patients with T2DM and CAD. Patients were recruited from the outpatient cardiology clinic of our hospital. All patients who met inclusion criteria underwent screening to define their degree of posttreatment platelet reactivity and identify patients with suboptimal clopidogrel-induced antiplatelet effects (study time point 1). Only patients with suboptimal clopidogrel responses were eligible for randomization. With the use of a computer-based randomization system, suboptimal clopidogrel responders were assigned to receive a daily clopidogrel maintenance dose with either 150 mg (two 75-mg tablets) or 75 mg (one 75-mg tablets). After randomization, the assigned clopidogrel maintenance dose regimen was maintained for 30 days, at which time platelet function was reassessed (study time point 2). Thereafter, all patients resumed the standard 75-mg daily dose and platelet function was assessed once again after 30 days (study time point 3). The flow-diagram of the study is represented in Figure 1. Patient compliance to antiplatelet treatment was assessed by interview and pill counting.

Blood sampling was performed 2 to 4 hours after drug intake. Samples were processed within 1 hour after blood drawing by operators blind to patient’s treatment assignment. Laboratory personnel were also blinded to treatment assignments.

The study complied with the Declaration of Helsinki, was approved by the Institutional Review Board of the University of Florida College of Medicine Jacksonville, and all patients gave their informed written consent. An independent data safety monitoring committee was instituted for adjudication of adverse clinical events. The authors had full access to the data and take full responsibility for their integrity. All authors have read and agree to the manuscript as written.

Platelet Function Analysis

Blood samples for platelet function assays were collected from an antecubital vein using a 21-gauge needle 2 to 4 hours after antiplatelet therapy intake. The first 2 to 4 mL of blood were discarded to avoid spontaneous platelet activation. Platelet function measures...
included assessments of platelet aggregation and the P2Y<sub>12</sub> reactivity ratio. Platelet aggregation was performed with light transmittance aggregometry in all patients according to standard protocols. In brief, blood was collected in sodium-citrated tubes. Platelet aggregations were assessed with platelet-rich plasma (PRP) by the turbidimetric method in a 2-channel aggregometer (Chrono-Log 490 Model, Chrono-Log Corp, Havertown, Pa) after stimulation with 5 or 20 μmol/L adenosine diphosphate (ADP). PRP obtained as a supernatant after centrifugation of citrated blood at 800 rpm for 10 minutes. The isolated PRP was kept at 37°C before use. Platelet-poor plasma was obtained by a second centrifugation of the blood fraction at 2500 rpm for 10 minutes. The platelet count in PRP was adjusted to the range of 250 000/μL by dilution with autologous plasma when platelet count was out of range. Light transmission was adjusted to 0% with PRP and to 100% platelet-poor plasma for each measurement. Curves were recorded for 6 minutes. Aggregation was measured at maximal aggregation (Agg<sub>max</sub>) and at 5 minutes (Agg<sub>5</sub>). Agg<sub>max</sub> is reflective of the activity of both the P2Y<sub>12</sub> receptor and platelet aggregation and P2Y<sub>12</sub> receptor in stabilization of the platelet aggregates purinergic receptors. However, clopidogrel only blocks the P2Y<sub>12</sub> receptor. Therefore, Agg<sub>5</sub> is more reflective of the activity of the P2Y<sub>12</sub> receptor and stabilization of aggregation. Inhibition of platelet aggregation (IPA) was defined as the percent decrease in aggregation values (Agg<sub>max</sub> and Agg<sub>5</sub>) obtained at baseline and after treatment: IPA (%) = (intensity of aggregation at baseline) − (intensity of aggregation at 30 days) ÷ (intensity of aggregation at baseline).

The primary end point of the study was Agg<sub>max</sub> after stimulus with 20 μmol/L ADP; IPA of Agg<sub>max</sub> and Agg<sub>5</sub> after stimulus with 5 and 20 μmol/L ADP; disaggregation after stimulus of 5 and 20 μmol/L ADP; and P2Y<sub>12</sub> reactivity ratio. Inter-and intragroup group comparisons of these platelet function measures were performed at various time points.

**Statistical Analysis**

Normally distributed continuous variables are presented as means±SD. Variables were analyzed for a normal distribution with the Kolmogorov-Smirnov test. Categorical variables are expressed as frequencies and percentages. Differences between groups were assessed with the Fisher exact test for categorical variables. Paired t tests were used for comparison of normally distributed continuous variables in the same group. Unpaired t tests were used for comparison of normally distributed continuous variables between the 2 groups. P<0.05 was considered statistically significant. Statistical analysis was performed with SPSSv14.0 software (SPSS Inc. Chicago, Ill).

**Results**

Platelet function screening was performed in a total of 64 patients with an Agg<sub>max</sub> of 58.05±14.5% induced by 20 μmol/L ADP. Of these, 40 patients (62.5%) showed suboptimal clopidogrel response and were randomized. At study time point 1, Agg<sub>max</sub> induced by 20 μmol/L ADP was 66.2±8% in the 40 patients with suboptimal clopidogrel response, versus 39.9±8% in the remaining 24 patients not eligible for randomization. No differences in baseline demographics existed between patients eligible and ineligible for randomization (data not shown). Baseline demographics of patients randomized to daily clopidogrel maintenance doses of 75 mg (n=20) versus 150 mg (n=20) are shown in Table 1. No differences in baseline characteristics existed except for slightly higher age in patients randomized to the maintenance dose of 150 mg clopidogrel. Use of CYP3A4- and non–CYP3A4-metabolizing statins was similar between the 2 groups. CYP3A4-metabolizing statins were not associated with clopidogrel-induced antiplatelet effects in the present study. Platelet counts (10<sup>9</sup>/L) were similar between the 2 groups: 307±86 (75-mg group) versus 279±54 (150-mg group) (P=0.21). All patients were compliant and responsive to aspirin. No bleeding complications occurred during the study. No changes in medical therapy, which included T2DM medications or antianginal therapy, occurred during the study. Finally, no patients interrupted clopidogrel or aspirin therapy as a result of side effects.

**Maximal ADP-Induced Platelet Aggregation Profiles**

No differences existed in baseline (study time point 1) Agg<sub>max</sub> after stimulus with 20 μmol/L ADP between the 2 groups (Table 2). One month after randomization (study time point 2), patients assigned to a clopidogrel maintenance dose of 150 mg experienced a significant reduction in Agg<sub>max</sub> compared with their baseline values and compared with patients randomized to a dose of 75 mg (P=0.002; Figure 2). No changes in Agg<sub>max</sub> were observed among patients randomized to standard dosing. Eight patients in the 150-mg maintenance dose group (40%) had an Agg<sub>max</sub> after stimulus with 20 μmol/L ADP <50% at study time point 2 versus none in the 75-mg dose group. Intergroup comparisons also showed higher IPA in the 150-mg maintenance dose group (Figure 3A). Cumulative distribution curves of changes in Agg<sub>max</sub> and IPA after stimulus with 20 μmol/L ADP illustrate the
Agglate were observed in the 75-mg group at all study time points. A significant reduction in Aggmax, whereas no significant changes were observed in patients kept on standard dosing (Table 2). Intergroup comparison showed lower posttreatment platelet reactivity (Table 2) and higher IPA (Figure 3A) in the high maintenance group.

At study time point 3, patients assigned to 150-mg dose experienced a return to Aggmax values comparable to those observed at baseline after a switch back to standard dosing (Table 2). In patients assigned to standard dosing, no significant differences in platelet aggregation existed at all 3 study time points (Table 2), a finding that demonstrated a persistent suboptimal response to standard clopidogrel maintenance dose.

Late ADP-Induced Platelet Aggregation Profiles

No differences existed in baseline (study time point 1) Aggmax parameters between the 2 groups (Table 2). One month after randomization (study time point 2), patients assigned to a 150-mg clopidogrel maintenance dose experienced a 20% and 15% reduction in Aggmax after stimulus with 20 and 5 μmol/L ADP, respectively (Table 2). No significant changes were observed in patients on the 75-mg dose (Table 2). Intergroup comparison also showed lower platelet reactivity (Table 2) and higher IPA (Figure 3B) in patients assigned to a 150-mg dose at study time point 2. At study time point 3, results paralleled those of Aggmax (Table 2).

Platelet Disaggregation

Disaggregation of ADP-aggregated platelets by clopidogrel was similar in both groups at baseline after stimulus with 20 and 5 μmol/L (Figure 5). One month after randomization, patients assigned to a high clopidogrel maintenance dose experienced an increase in platelet disaggregation, whereas no significant changes were observed in patients kept on standard dosing (Figure 5). Enhanced platelet disaggregation

---

TABLE 1. Demographics of the Study Population

<table>
<thead>
<tr>
<th>Age, y</th>
<th>75 mg (n=20)</th>
<th>150 mg (n=20)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>59±10</td>
<td>64±8</td>
<td>0.05</td>
<td></td>
</tr>
<tr>
<td>Male, n (%)</td>
<td>14 (70)</td>
<td>12 (60)</td>
<td>0.75</td>
</tr>
<tr>
<td>Race, n (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>11 (55)</td>
<td>13 (65)</td>
<td>0.75</td>
</tr>
<tr>
<td>Black</td>
<td>8 (40)</td>
<td>6 (30)</td>
<td>0.74</td>
</tr>
<tr>
<td>Hispanic</td>
<td>1 (5)</td>
<td>1 (5)</td>
<td>1.00</td>
</tr>
<tr>
<td>Risk factors/past medical history, n (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Insulin-dependent diabetes mellitus</td>
<td>6 (30)</td>
<td>8 (40)</td>
<td>0.74</td>
</tr>
<tr>
<td>Non-insulin-dependent diabetes mellitus</td>
<td>14 (70)</td>
<td>12 (60)</td>
<td>0.74</td>
</tr>
<tr>
<td>HbA1C</td>
<td>7.0±1.1</td>
<td>7.1±1.5</td>
<td>0.93</td>
</tr>
<tr>
<td>Smoking</td>
<td>4 (20)</td>
<td>3 (15)</td>
<td>1.00</td>
</tr>
<tr>
<td>Hyperlipidemia</td>
<td>19 (95)</td>
<td>18 (90)</td>
<td>1.00</td>
</tr>
<tr>
<td>Hypertension</td>
<td>19 (95)</td>
<td>18 (90)</td>
<td>1.00</td>
</tr>
<tr>
<td>Body mass index, kg/m²</td>
<td>32.4±7</td>
<td>33.5±6</td>
<td>0.61</td>
</tr>
<tr>
<td>Prior myocardial infarction</td>
<td>8 (40)</td>
<td>7 (35)</td>
<td>1.00</td>
</tr>
<tr>
<td>Prior CABG</td>
<td>4 (20)</td>
<td>5 (25)</td>
<td>1.00</td>
</tr>
<tr>
<td>Multivessel CAD</td>
<td>15 (75)</td>
<td>14 (70)</td>
<td>1.00</td>
</tr>
<tr>
<td>Treatment, n (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>β-Blockers</td>
<td>17 (85)</td>
<td>16 (80)</td>
<td>0.74</td>
</tr>
<tr>
<td>Nitrates</td>
<td>6 (30)</td>
<td>8 (40)</td>
<td>1.00</td>
</tr>
<tr>
<td>ACE inhibitors/ARB</td>
<td>13 (65)</td>
<td>14 (70)</td>
<td>1.00</td>
</tr>
<tr>
<td>Lipid-lowering agents</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CYP3A4 metabolizing statin</td>
<td>17 (85)</td>
<td>15 (75)</td>
<td>0.69</td>
</tr>
<tr>
<td>Non-CYP3A4 metabolizing statin</td>
<td>1 (5)</td>
<td>4 (20)</td>
<td>0.34</td>
</tr>
</tbody>
</table>

HbA1C indicates hemoglobin A1C; CAD, coronary artery disease; CABG, coronary artery bypass grafting; ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blockers; and CYP3A4, cytochrome P450 3A4 isoenzyme.

Values are expressed as mean±SD unless otherwise indicated.

---

TABLE 2. Aggmax and Agglate Values After Stimulus With 20 μmol/L and 5 μmol/L ADP in Patients Randomized to a Standard (75 mg) or High (150 mg) Daily Maintenance Dose

<table>
<thead>
<tr>
<th>Study Time Point 1</th>
<th>Study Time Point 2</th>
<th>Study Time Point 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>75 mg</td>
<td>150 mg</td>
<td></td>
</tr>
<tr>
<td>20 μmol/L ADP</td>
<td>5 μmol/L ADP</td>
<td>20 μmol/L ADP</td>
</tr>
<tr>
<td>Aggmax</td>
<td>Aggmax</td>
<td>Aggmax</td>
</tr>
<tr>
<td>64.9±9</td>
<td>59.7±12</td>
<td>63.1±7</td>
</tr>
<tr>
<td>P</td>
<td>0.32</td>
<td>0.002</td>
</tr>
<tr>
<td>150 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>67.4±6</td>
<td>63.2±7</td>
<td>52.3±13*</td>
</tr>
<tr>
<td>P</td>
<td>0.05</td>
<td>0.97</td>
</tr>
</tbody>
</table>

Values are expressed as mean±SD of percentage (%) platelet aggregation. P values reported in the table refer to intergroup comparisons. At study time point 2, patients in the 150-mg dose group had Aggmax and Agglate significantly lower versus study time points 1 and 3 (*P<0.001 for intra- and intergroup comparisons). Intra- and intergroup comparisons showed no differences in Aggmax and Agglate between study time points 1 and 3. Intergroup comparisons of Aggmax and Agglate at study time point 2 in the 75-mg dose group were not different from values at study time points 1 and 3 in the 150-mg dose group. No differences in Aggmax and Agglate were observed in the 75-mg group at all study time points.
was observed in patients assigned to a 150-mg versus those receiving a 75-mg maintenance dose. Thirty days after discontinuation of high clopidogrel dose, disaggregation values returned to values comparable with baseline (Figure 5).

**P2Y\textsubscript{12} Reactivity Ratio**

At baseline (study time point 1), the P2Y\textsubscript{12} reactivity ratio was similar in patients randomized to standard and high clopidogrel maintenance dosing (Figure 6). One month after randomization (study time point 2), the P2Y\textsubscript{12} reactivity ratio significantly reduced in patients assigned to the high clopidogrel maintenance dose regimen; the P2Y\textsubscript{12} reactivity ratio was also lower compared with patients kept on standard dosing. The P2Y\textsubscript{12} reactivity ratio returned to values comparable with baseline in patients randomized to a high clopidogrel maintenance dose regimen after resumption of a standard clopidogrel maintenance dose, whereas no significant changes were observed in patients on standard dosing (Figure 6).

**Discussion**

This randomized prospective study is the first to confirm the hypothesis that a high maintenance dose (150 mg daily) of clopidogrel in a high-risk group of patients with T2DM and CAD enhances platelet inhibition, as assessed by multiple biological determinants of platelet function, compared with a standard dose (75 mg daily). The dose-dependent effect of clopidogrel was confirmed by the return to baseline values of all platelet function measures after discontinuation of the high-dose regimen and recommencement of standard dosing. However, despite an overall improvement in platelet function profiles among patients randomized to a high maintenance dose of clopidogrel, response to antiplatelet therapy remained variable and a considerable proportion of patients persisted with enhanced platelet reactivity. In addition, our study provides further evidence that most patients with T2DM continue to exhibit increased platelet reactivity despite dual antiplatelet therapy, which makes this high-risk group a target population for evaluation of more aggressive antiplatelet treatment regimens.

In patients diagnosed with acute coronary syndromes and/or treated with percutaneous coronary interventions, adjunctive treatment with clopidogrel in combination with aspirin has been shown to be superior to aspirin alone for secondary prevention of ischemic events, including in patients with diabetes mellitus.\textsuperscript{3,4} In addition, clopidogrel has been shown to be superior to aspirin, especially in patients with diabetes mellitus.\textsuperscript{2,20} However, despite the clinical benefit associated with clopidogrel treatment, diabetic patients continue to have a higher risk of ischemic events compared with nondiabetic patients, a difference that may be attributed, at least in part, to suboptimal responsiveness to antiplatelet therapy.\textsuperscript{18,19}

Suboptimal clopidogrel-induced antiplatelet effects observed with currently recommended dosing regimens have been reported by various investigators with the suggestion that they contribute to poor clinical outcomes.\textsuperscript{5-12} Dose-finding studies that support the currently recommended doses of clopidogrel were designed to achieve a level of platelet inhibition similar to 500 mg of ticlopidine per day.\textsuperscript{30} These dose-finding studies did not take into consideration the prothrombotic milieu of high-risk subjects, such as T2DM. Previous reports have shown that suboptimal clopidogrel responsiveness poses considerable risk of ischemic events.\textsuperscript{7-10,28,31} High loading doses (\(\geq 600 \text{ mg}\)) have been proposed as a strategy to accelerate and enhance platelet inhibition compared with a standard loading dose of 300 mg and to improve short-term clinical outcomes compared with standard clopidogrel therapy.\textsuperscript{11-14} However, the antiplatelet effects of clopidogrel front-loading are confined to the initial phase of therapy, and patients rely on their daily maintenance dose for long-term prevention of ischemic events. Our study confirms that a long-term maintenance strategy with standard recommended doses is suboptimal in most patients with T2DM and CAD. Furthermore, our study shows that improvements in
platelet inhibition are transient and confined to the period of high doses of clopidogrel therapy, and that high platelet reactivity is a persistent state in these patients.

Patients with T2DM have increased platelet reactivity and reduced in vitro responsiveness to antiplatelet agents, which include P2Y12 receptor antagonists, compared with nondiabetic subjects. Numerous mechanisms can account for platelet dysfunction in T2DM. In vitro studies have shown that insulin reduces platelet aggregation by inhibition of the P2Y12 pathway. In fact, human platelets are targets of the effects of insulin, which interacts with its own receptor on the platelet surface and leads to loss of Gi activity. This loss reduces suppression of cyclic adenosine monophosphate, which thus inhibits P2Y12 signaling and reduces platelet reactivity. However, platelets of T2DM patients are also targets of the insulin resistance phenomenon that typically affects T2DM patients and results in decreased sensitivity to insulin. This decreased sensitivity leads to upregulation of the P2Y12 pathway and increased platelet reactivity in diabetic platelets. Other mechanisms responsible for suboptimal clopidogrel-induced antiplatelet effects in T2DM include increased exposure to ADP, increased cytosolic levels of calcium, and increased platelet turnover.

Suboptimal responsiveness to clopidogrel represents an emerging clinical entity. This phenomenon has been associated with recurrence of ischemic events, which include stent thrombosis. Stent thrombosis may lead to severe consequences and has become a major concern in the era of drug-eluting stents. Importantly, diabetes mellitus has been identified as an independent predictor of stent thrombosis. Current guidelines (class IIb indication, level of evidence C) state that in patients in whom stent thrombosis may be catastrophic or lethal, platelet aggregation studies may be considered and the dose of clopidogrel increased to 150 mg per day if >50% inhibition of platelet aggregation is demonstrated. A similar approach may be utilized in clinical practice, but essentially no data exist on the efficacy, either biological or clinical, of this treatment regimen.

The present study provides the first biological evidence that 150 mg of clopidogrel may indeed improve platelet inhibition in high-risk patients who are suboptimal responders under current standard antiplatelet therapy. Nevertheless, our study also shown that more than half of the patients continued to exhibit platelet aggregation >50%, which has been considered a therapeutic threshold for P2Y12 inhibition. These findings highlight the potential need for more effective antithrombotic strategies to tackle the diabetic platelet and that individualized therapy may be required.

However, individualized therapy with higher maintenance doses of current medications or with additional or more potent antiplatelet agents is not yet supported by clinical studies. Furthermore, large-scale clinical studies have clearly shown the benefit of standard antiplatelet treatment regimens.

![Figure 3. Inhibition of maximal (A) and late (B) platelet aggregation between baseline (study time point 1) and 30 days (study time point 2) assessed after stimulus with 20 μmol/L and 5 μmol/L ADP in patients randomized to clopidogrel maintenance doses of 75 mg and 150 mg. Values are expressed as percentage (%) of platelet aggregation. Error bars indicate standard deviations of the mean.](http://circ.ahajournals.org/)

![Figure 4. Cumulative distribution curves of change of maximal platelet aggregation (A) and inhibition of maximal platelet aggregation (B) between baseline (study time point 1) and 30 days (study time point 2) after stimulus with 20 μmol/L ADP in patients randomized to clopidogrel maintenance doses of 75 mg and 150 mg. Values are expressed as percentage (%) platelet aggregation. Boxes represent individual changes.](http://circ.ahajournals.org/)
in diabetic patients, as recommended in current guidelines, and the results of this pilot ex vivo platelet function analysis should not lead physicians to change their medical practice, as they have not been shown to have clinical implications.\textsuperscript{2–4,29,34} Novel and more potent oral P2Y\textsubscript{12} receptor antagonists and drugs that inhibit platelet thrombin receptors are currently under clinical investigation and have been shown to have less response variability. These agents may represent potential future alternatives for treating these high-risk patients.\textsuperscript{36,37}

**Conclusion**

In conclusion, this study demonstrates that the currently recommended maintenance dose of clopidogrel is associated with a high incidence of suboptimal response among patients with T2DM and CAD. Based on the results of various platelet function assessments, our study demonstrates the overall biological effectiveness of a 150-mg maintenance dose regimen compared with standard doses of 75 mg in high-risk patients. At the same time, our study found that some patients continue to show high platelet aggregation levels despite increased doses of clopidogrel, a finding that suggests the need for further improvement in our antiplatelet strategies, the clinical implications of which need to be evaluated in large-scale clinical trials.

**Study Limitations**

The present study did not account for performance of multiple significance tests or for potential correlation among various measures of platelet function. Also, our study was not powered to evaluate the risk of bleeding with the use of high-dose clopidogrel in association with aspirin. Thus, the lack of adverse effects in the present study should be interpreted with caution. In addition, the study was not designed to measure clinical outcomes. Therefore, the results of this pilot study need to be considered as exploratory and our laboratory findings should not be applied to clinical practice. Before development of large randomized clinical effectiveness trials that test aggressive antiplatelet therapy, the safety and biological effectiveness, as comprehensively investigated in the present study, of such strategies must be determined. Ultimately, numerous definitions have been reported to describe clopidogrel-induced antiplatelet effects. However, recent studies suggest that posttreatment platelet reactivity rather than responsiveness is a better determinant of ischemic risk.\textsuperscript{10,38} Given that our patient population was composed of patients already treated with clopidogrel, post-treatment platelet reactivity was the most applicable definition of poor response to clopidogrel-induced antiplatelet
effects in our study. In addition, the methods and cut-off values used in our study have been shown to identify patients at highest risk of development of future ischemic events, and this work has been suggested as a therapeutic guide in clopidogrel-treated patients.  

**Sources of Funding**  
This study was funded by a University of Florida College of Medicine at Jacksonville Research Grant (2005/70992). Dr Angiolillo received the 2005 Stop Heart Disease Researcher of the Year Award sponsored by the Florida Heart Research Institute and Florida Chapter of the American College of Cardiology.

**Disclosures**  
Dr Angiolillo and Dr Zenni are on the speakers’ bureau and the consultant/advisory board for Bristol Myers Squibb and Sanofi-Aventis. The other authors report no conflicts.

**References**


CLINICAL PERSPECTIVE

Suboptimal response to antiplatelet agents is an emerging clinical entity. Recent investigations have focused on identification of patients with suboptimal antiplatelet drug response. In particular, numerous investigations have identified patients with diabetes mellitus (DM) to exhibit reduced platelet inhibition compared with non-DM patients treated with recommended doses of antiplatelet agents. These findings may explain why DM patients continue to have an increased atherothrombotic risk even with the use of antiplatelet agents. Results from recent investigations demonstrate that selective use of specific antiplatelet agents or modification of their dosage may improve functional response profiles in DM patients. In particular, the Optimizing anti-Platelet Therapy In diabetes MellitusUS (OPTIMUS) study demonstrates that specific targeting of the upregulated P2Y12 pathway by platelets from high-risk DM patients, with a higher clopidogrel maintenance dosage, significantly increases platelet inhibition. However, a considerable number of patients continue to exhibit enhanced platelet reactivity. Whether the laboratory findings from this study translate into better clinical outcomes without an increase in bleeding hazards warrants further investigation. Future investigations will need to evaluate how specific blockade of dysfunctional targets of the diabetic platelet as well as tackling plasmatic components extrinsic to the platelet (i.e., thrombin), but which contribute to platelet activation and thrombosis, will hamper the prothrombotic status of these high-risk patients. Hopefully, this will lead to an era of individualized antithrombotic treatment regimens to overcome the “one size fits all” concept, performed through routine measurements of platelet activity in the same way that blood sugar, blood pressure, and cholesterol are followed to help guide therapy.
Randomized Comparison of a High Clopidogrel Maintenance Dose in Patients With Diabetes Mellitus and Coronary Artery Disease: Results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) Study
Dominick J. Angiolillo, Steven B. Shoemaker, Bhaloo Desai, Hang Yuan, Ronald K. Charlton, Esther Bernardo, Martin M. Zenni, Luis A. Guzman, Theodore A. Bass and Marco A. Costa

Circulation. 2007;115:708-716; originally published online January 29, 2007; doi: 10.1161/CIRCULATIONAHA.106.667741

Circulation is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2007 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circ.ahajournals.org/content/115/6/708

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation is online at:
http://circ.ahajournals.org/subscriptions/